...
首页> 外文期刊>BMC Veterinary Research >Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs
【24h】

Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs

机译:对脂肪体 - TLR激动剂免疫治疗粘膜施用的局部免疫和微生物反应

获取原文

摘要

Non-specific immunotherapeutics have been evaluated previously in dogs, primarily for cancer treatment. However, there remains a need for a more broadly targeted, general purpose immunotherapeutic capable of activating innate immune defenses for non-specific protection or early treatment of viral and bacterial infections. To address need, our group has developed a liposomal immune stimulant (liposome-TLR complexes, LTC) containing TLR 3 and 9 agonists specifically designed to activate mucosal immune defenses in sites such as nasal cavity and oropharynx, following topical delivery. In this study, we evaluated the local immune stimulatory properties of LTC in vitro and in healthy purpose-bred dogs, including activation of cellular recruitment and cytokine production. The ability of LTC treatment to elicit effective antiviral immunity was assessed in dogs following a canine herpesvirus outbreak, and the impact of LTC treatment on the local microbiome of the oropharynx was also investigated. These studies revealed that LTC potently activated innate immune responses in vitro and triggered significant recruitment of inflammatory monocytes and T cells into the nasal cavity and oropharynx of healthy dogs. Administration of LTC to dogs shortly after an outbreak of canine herpesvirus infection resulted in significant reduction in clinical signs of infection. Interestingly, administration of LTC to healthy dogs did not disrupt the microbiome in the oropharynx, suggesting resiliency of the microflora to transient immune activation. Taken together, these results indicate that LTC administration mucosally to dogs can trigger local innate immune activation and activation of antiviral immunity, without significantly disrupting the composition of the local microbiome. Thus, the LTC immune stimulant has potential for use as a non-specific immunotherapy for prevention or early treatment of viral and bacterial infections in dogs.
机译:已经在狗中评估了非特异性免疫治疗剂,主要用于癌症治疗。然而,仍然需要一种更广泛的靶向的通用免疫治疗,能够激活用于非特异性保护或早期治疗病毒和细菌感染的先天免疫防御。为了满足需求,我们的小组开发了含有TLR 3和9个激动剂的脂质体免疫刺激剂(LIPOSOME-TLR络合物,LTC),该激动剂专门设计用于在局部递送之后激活鼻腔和Oropharynx等鼻腔中的粘膜免疫防御。在这项研究中,我们在体外和健康目的养犬中评估了LTC的局部免疫刺激特性,包括激活细胞募集和细胞因子产生。在犬群疱疹病毒爆发后,在狗患者中评估了LTC治疗引发有效抗病毒免疫力的能力,并研究了LTC治疗对口咽局部微生物组的影响。这些研究表明,LTC在体外有效地活化先天免疫应答,并引发了炎症单核细胞和T细胞的显着募集到健康犬的鼻腔和oropharynx中。在犬疱疹病毒感染爆发后不久将LTC给狗施用导致临床感染症状的显着降低。有趣的是,LTC给健康犬的给药并没有破坏Oropharynx中的微生物组,这表明微生物的弹性对短暂的免疫活化。总之,这些结果表明,LTC给予盲螨的粘膜可以引发局部先天免疫激活和抗病毒力免疫激活,而不是显着破坏局部微生物组的组成。因此,LTC免疫刺激剂具有用作非特异性免疫疗法,用于预防或早期治疗犬病毒和细菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号